atypical disease and metastatic disease. Aim of the study is to explore the benefit of adjuvant therapy for thoracic carcinoid tumors. Methods: A literature review was conducted through PubMed in accordance with PRISMA guidelines to identify studies
Search Results
Philip Sobash and Nagla Abdel Karim
Baylee F. Bakkila, Daniel Kerekes, Caroline H. Johnson, and Sajid A. Khan
, adequate lymphadenectomies as per National Comprehensive Cancer Network guidelines and use of adjuvant therapy. Multivariable logistic regressions were fit to determine differences in quality of care by insurance and when controlling for covariates (sex
Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, and Ching-Kun Wang
48.5 months for the EGFRm negative group (rwDFS event rate: 46.3%) and unknown EGFRm status (rwDFS event rate: 49.7%), respectively. After adjustment for key patient covariates; disease stage and adjuvant therapy status were significantly associated
of capecitabine + oxaliplatin was added as an option in adjuvant therapy with a category 2A designation. Footnote “j” was clarified by adding “exclusive of those cancers that are MSI-H” to grade 3-4. Surveillance Chest
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on
scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Randomized Phase II Study Comparing Concise (3 Months) Versus Prolonged (2 Years) Afatinib as Adjuvant Therapy for
Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks
. 5 Coates AS Keshaviah A Thurlimann B . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 . J Clin Oncol 2007 ; 25 : 486
Nora M. Hansen, Sally Anne Scherer, and Seema Khan
of 60 cases, care was nonconcordant in 8. Among those cases, 1 patient was advised to have chemotherapy but refused; another patient’s record did not document a recommendation for adjuvant therapy; and 5 patients received treatment but not within the
Margaret Tempero
margin,” she said. Dr. Tempero briefly reviewed some of the representative adjuvant therapy clinical trials conducted in pancreatic cancer, focusing primarily on the relatively recent phase III ESPAC-4 trial of gemcitabine/capecitabine 1 and the
Margaret Tempero
reason that in the adjuvant setting, we could probably identify diagnostic tools to predict outcome, and thus need for adjuvant treatment, across all disease sites. Actually, folks are working on that with a fair bit of success. But adjuvant therapy is
